Modulation of human α4β2 nicotinic acetylcholine receptors by brominated and halogen-free flame retardants as a measure for in vitro neurotoxicity.

Toxicol Lett

Neurotoxicology Research Group, Toxicology Division, Institute for Risk Assessment Sciences, Faculty of Veterinary Medicine, Utrecht University, P.O. Box 80.177, NL-3508 TD Utrecht, The Netherlands.

Published: September 2012

Brominated flame retardants (BFRs) are abundant persistent organic pollutants with well-studied toxicity. The toxicological and ecological concern associated with BFRs argues for replacement by safer alternatives. However, the (neuro)toxic potential of alternative halogen-free flame retardants (HFFRs) is unknown. Previous research identified the nervous system as a sensitive target organ for BFRs, with modulation of excitatory nicotinic acetylcholine (nACh) receptors as one of the modes of action. Since it is essential to assess the (neuro)toxic potential of HFFRs before large scale use, we measured the effects of three BFRs and 13 HFFRs on the function of human α(4)β(2) nACh receptors, expressed in Xenopus oocytes, using the two-electrode voltage-clamp technique. The results demonstrate that some BFRs (TBBPA and to a lesser extent BDE-209) and HFFRs (TPP, Alpi, APP, MMT and to a lesser extent ATH, ATO, MHO, MPP, RDP and ZHS) act as nACh receptor antagonists. Contrary, BPS, BDP, DOPO and ZS were unable to modulate nACh receptors. Despite the lack of toxicological data on HFFRs and the need for additional studies to perform a full (neuro)toxic risk assessment, the current data on antagonistic effects on nACh receptors could be an important step in prioritizing viable HFFRs for substitution of BFRs.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.toxlet.2012.06.013DOI Listing

Publication Analysis

Top Keywords

nach receptors
16
flame retardants
12
human α4β2
8
nicotinic acetylcholine
8
halogen-free flame
8
neurotoxic potential
8
lesser extent
8
bfrs
6
hffrs
6
receptors
5

Similar Publications

This article provides a comprehensive overview of the current treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) following the failure of first-line therapy. Although significant progress has been made in the primary treatment of hormone-sensitive prostate cancer, the management of mCRPC remains a clinical challenge. The article outlines the diagnostic criteria for mCRPC, which can be confirmed through biochemical progression and imaging techniques.

View Article and Find Full Text PDF
Article Synopsis
  • A meta-analysis was conducted to compare the effectiveness of sacubitril-valsartan (S/V) versus angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) in preventing recurrent atrial fibrillation (AF) after catheter ablation.
  • The study included four clinical trials with 642 total patients, showing that the S/V group had a significantly lower rate of persistent AF (RR: 0.54) and a reduction in left atrial volume compared to the ACEI/ARB group.
  • While S/V appears more effective in reducing AF recurrence, the left ventricular ejection fraction did not differ significantly between the two treatments, highlighting the need for
View Article and Find Full Text PDF

[Hand-foot syndrome after taking fibroblast growth factor receptor 2 inhibitor].

Dermatologie (Heidelb)

October 2024

Klinik und Poliklinik für Dermatologie und Allergologie, Klinikum der Universität München, LMU München, Frauenlobstr. 9-11, 80337, München, Deutschland.

View Article and Find Full Text PDF

Objectives: Neurological disorders represent a significant global health challenge, necessitating the exploration of novel therapeutic agents. Apigenin, a natural flavonoid abundantly found in various plants, has garnered attention for its potential neuroprotective properties. In this study, we employed molecular docking simulations to investigate the interaction between apigenin and key molecular targets associated with neurological disorders.

View Article and Find Full Text PDF

Galantamine suppresses α-synuclein aggregation by inducing autophagy via the activation of α nicotinic acetylcholine receptors.

J Pharmacol Sci

October 2024

Pharmacology and Neurobiology Laboratory, College of Pharmaceutical Sciences, Ritsumeikan University, 1-1-1 Noji-Higashi, Kusatsu, Shiga, 525-8577, Japan. Electronic address:

Article Synopsis
  • Synucleinopathies like Parkinson's disease and dementia involve problems in the brain caused by a protein called α-synuclein.
  • Currently, there are no effective treatments for these disorders, but researchers found that a drug called galantamine might help by preventing harmful protein buildup.
  • Studies showed that galantamine could protect brain cells and stop the spread of α-synuclein in mice, which means it could be a promising new treatment option.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!